

RECEIVED
CENTRAL FAX CENTER
JAN 21 2010

Applicants : Robert L. Fine et al.
U.S. Serial No.: 10/587,606
Filed : November 13, 2006
Page : 2 of 13 of Amendment

Amendments to the Claims:

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A polypeptide comprising ~~continuous~~ consecutive amino acids, ~~a segment of which has the~~ sequence
AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGET
KFMLKKHRSTSQGKKSKLHSSHARSGGPEKGAQA (SEQ ID NO. 3),
wherein the glycine may be present or absent.
2. (Cancelled)
3. (Original) The polypeptide of claim 1, further comprising a six repeat histidine tag attached to the N-terminus of the polypeptide.
4. (Original) The polypeptide of claim 1, further comprising a membrane carrier peptide attached to the C-terminus of the polypeptide.
5. (Currently Amended) The polypeptide of claim 4, wherein the membrane carrier peptide ~~(Ant)~~ comprises amino acids ~~having the sequence~~ KKWKMRRNQFWVKVQRG (SEQ ID NO. 8).
6. (Original) The polypeptide of claim 1, further comprising:

Applicants : Robert L. Fine et al.
U.S. Serial No.: 10/587,606
Filed : November 13, 2006
Page : 3 of 13 of Amendment

- a. a six repeat histidine tag attached to the N-terminus of the polypeptide; and
 - b. a membrane carrier peptide attached to the C-terminus of the polypeptide.
7. (Cancelled).
8. (Cancelled).
9. (Currently Amended) The polypeptide of claim 1, comprising consecutive amino acids ~~having the sequence~~ AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKFMLKKHRSTSQGKKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKFMLKKHRSTSQGKSKLHSSHARSGGPEKGAQA (SEQ ID NO. 5), wherein each glycine may be present or absent.
10. (Original) The polypeptide of claim 9, further comprising a six repeat histidine tag attached to the N-terminus of the polypeptide.
11. (Original) The polypeptide of claim 9, further comprising a membrane carrier peptide attached to the C-terminus of the polypeptide.
12. (Currently Amended) The polypeptide of claim 11, wherein the membrane carrier peptide comprises amino acids having the sequence KKWKMRRNQFWVKVQRG (SEQ ID NO. 8).
13. (Original) The polypeptide of claim 9, further comprising:

Applicants : Robert L. Fine et al.
U.S. Serial No.: 10/587,606
Filed : November 13, 2006
Page : 4 of 13 of Amendment

- a. a six repeat histidine tag attached to the N-terminus of the polypeptide; and
 - b. a membrane carrier peptide attached to the C-terminus of the polypeptide.
14. (Currently Amended) The polypeptide of claim 1, comprising consecutive amino acids ~~having the sequence~~ DSDPGETKFMLKKHRSTSQGKKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEP GGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKFMLKKH RSTSQGKKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEP GGSRAHSSHLKSKK GQSTSRHKKLMFKTEGPDSD (SEQ ID NO. 6), wherein each glycine may be present or absent.
15. (Original) The polypeptide of claim 14, further comprising a six repeat histidine tag attached to the N-terminus of the polypeptide.
16. (Original) The polypeptide of claim 14, further comprising a membrane carrier peptide attached to the C-terminus of the polypeptide.
17. (Currently Amended) The polypeptide of claim 16, wherein the membrane carrier peptide comprises amino acids ~~having the sequence~~ KKWKMRNRFVVKVQRG (SEQ ID NO. 8).
18. (Original) The polypeptide of claim 14, further comprising:
- a. a six repeat histidine tag attached to the N-terminus of the polypeptide; and

Applicants : Robert L. Fine et al.
U.S. Serial No.: 10/587,606
Filed : November 13, 2006
Page : 5 of 13 of Amendment

- b. a membrane carrier peptide attached to the C-terminus of the polypeptide.

19-30. (Cancelled)

31. (Currently Amended) A method of treating a subject suffering from cancer by administering to the subject an amount of a the polypeptide of claim 1 comprising consecutive amino acids
AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGET
KFMLKKHRSTSQGKKSKLHSSHARSGGPEKGAQA (SEQ ID NO. 3),
wherein the glycine may be present or absent, effective to treat the cancer.

32-35. (Cancelled)

36. (Previously Presented) A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier for treating cancer.

37-40. (Cancelled)

41. (Currently Amended) A method of treating a subject suffering from cancer by comprising administering to the subject an amount of a the polypeptide of claim 9 comprising consecutive amino acids
AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGET
KFMLKKHRSTSQGKKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEPGGSRAHS
SHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKFMLKKHRSTSQK
KSKLHSSHARSGGPEKGAQA (SEQ ID NO. 5), wherein each glycine
may be present or absent, effective to treat the cancer.

Applicants : Robert L. Fine et al.
U.S. Serial No.: 10/587,606
Filed : November 13, 2006
Page : 6 of 13 of Amendment

42. (Currently Amended) A method of treating a subject suffering from cancer ~~by comprising~~ administering to the subject an amount of a the polypeptide of ~~claim 14~~ comprising consecutive amino acids
DSDPGETKFMLKKHRSTSQGKKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEP
GGSTRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKFMLKKH
RSTSQGKKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEP
GGSTRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD (SEQ ID NO. 6), wherein each glycine
may be present or absent, effective to treat the cancer.